Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.
|Articles|September 19, 2019
Schizophrenia Q&A: Depot Medications in Schizophrenia Therapy
Author(s)Peter F. Buckley, MD
Key Takeaways
- Clinical selection for depot antipsychotics is framed as a multifactorial decision tailored to individual patients with schizophrenia.
- A second focus is on actionable interventions that can increase acceptance and utilization of depot medications in clinical practice.
In this video segment, Dr. Peter Buckley addresses 2 questions: • What factors do you consider when you offer depot medications to a patient with schizophrenia? • What can be done to encourage the use of depot medications?
Advertisement
In this video clip, Dr Peter Buckley addresses 2 questions:
• What factors do you consider when you offer depot medications to a patient with schizophrenia?
• What can be done to encourage the use of depot medications?
This video was originally posted on June 19, 2012 and has since been updated with permission from Dr Buckley. -Ed
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
3
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
4
Brenipatide for Alcohol Use Disorder: Emerging Findings
5